

SYNGENTA AG  
Form 6-K  
November 15, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2016

Commission File Number: 001-15152

**SYNGENTA AG**

(Translation of registrant's name into English)

**Schwarzwaldallee 215**

**4058 Basel**

**Switzerland**

(Address of principal executive offices)

Edgar Filing: SYNGENTA AG - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

Re: SYNGENTA AG

Disclosure: **“Syngenta receives approval for breakthrough fungicide  
ADEPIDYN™ in Argentina”**

Herewith we furnish a press release related to Syngenta AG. The full text of the press release is the following:

###

**Syngenta International AG Media contacts:**

Media Office                      Leandro Conti  
CH-4002 Basel                    Switzerland +41 61 323 2323  
Switzerland  
Tel: +41 61 323 2323  
Fax: +41 61 323 2424              Paul Minehart  
USA                                  +1 202 737 8913

**Analyst/Investor contacts:**

Jennifer Gough  
Switzerland +41 61 323 5059  
USA                                  +1 202 737 6521

[www.syngenta.com](http://www.syngenta.com)

Basel, Switzerland, November 15, 2016

**Syngenta receives approval for breakthrough fungicide ADEPIDYN™ in Argentina**

First registration of a product based on ADEPIDYN™

Global peak sales potential estimated at more than \$750 million

ADEPIDYN™ based products to be marketed under the MIRAVIS™ brand

Syngenta announced today that MIRAVIS™ Duo, a combination of ADEPIDYN™ and difenoconazole, has been approved by SENASA (regulatory authority in Argentina), for use on soybean for late cycle diseases. This is the first registration for a product based on ADEPIDYN™, a new fungicide belonging to the carboxamide chemical class.

ADEPIDYN™ provides a step change in leaf spot disease management and delivers excellent control of powdery mildew. It is highly effective on difficult-to-control diseases such as Fusarium head blight and moulds which cause severe damage to the crop. Syngenta is currently developing several ADEPIDYN™ based products to address various

disease management challenges in soybean, wheat, corn, canola, vegetables and specialty crops around the world.

Jon Parr, President Global Crop Protection, Syngenta, said “MIRAVIS™ Duo builds on our strong fungicide heritage including ELATUS™ and AMISTAR™ Technology. By continuing to deliver industry-leading innovation to growers, we are strengthening our global leadership in fungicides.”

First sales of MIRAVIS™ Duo are expected in the 2016/2017 soybean season in Argentina. Regulatory approvals are pending in several other markets.

### **About Syngenta**

Syngenta is a leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Through world class science and innovative crop solutions, our 28,000 people in over 90 countries are working to transform how crops are grown. We are committed to rescuing land from degradation, enhancing biodiversity and revitalizing rural communities. To learn more visit [www.syngenta.com](http://www.syngenta.com) and [www.goodgrowthplan.com](http://www.goodgrowthplan.com). Follow us on Twitter® at [www.twitter.com/Syngenta](http://www.twitter.com/Syngenta).

***Cautionary Statement Regarding Forward-Looking Statements***

This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta – November 15, 2016 / Page 2 of 2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SYNGENTA AG

Date: November 15, 2016 By: /s/ Dr. Tobias Meili  
Name: Dr. Tobias Meili  
Title: Head Corporate Legal Affairs

By: /s/ Markus Widmer  
Name: Markus Widmer  
Title: Legal Counsel